Xerofung 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. Xerofung 200 is administered orally and exhibits good bioavailability, with enhanced absorption when taken with food. The drug is extensively metabolized in the liver via the cytochrome P450 system, necessitating caution when co-administered with other medications metabolized by the same pathway due to potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function should be monitored during prolonged therapy to detect hepatotoxicity early. Xerofung 200 should be used with caution in patients with hepatic impairment and is contraindicated in pregnancy due to potential teratogenic effects. Proper adherence to prescribed dosage and duration is essential to ensure therapeutic efficacy and minimize resistance development.